Pravastatin (cancer chemoprevention context; statin class proxy)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-PRAVASTATIN-CHEMOPREVENTION |
|---|---|
| Type | Drug |
| Aliases | LipostatPravacholPravastatin (cancer chemoprevention)Statin (pravastatin proxy)Правастатин (хіміопрофілактика раку; представник статинів) |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 SRC-WCRF-AICR-CUP-2018 |
Drug Facts
| Class | HMG-CoA reductase inhibitor (statin) — hydrophilic, first-generation |
|---|---|
| Mechanism | Hydrophilic active-form statin (administered as the open beta-hydroxy acid, not a prodrug); competitively inhibits HMG-CoA reductase. Cancer- prevention rationale: shared statin pleiotropic effects (decreased isoprenoid prenylation of Ras/Rho, anti-inflammatory, antiproliferative, pro-apoptotic). PROSPER trial substudy and other observational analyses have produced inconsistent cancer-incidence signals — some suggesting a small reduction in colorectal cancer, none reaching RCT- level certainty for any specific malignancy. Hydrophilic profile, minimal CYP metabolism, and well-tolerated muscle profile make it a preferred statin in patients on extensive polypharmacy. |
| Typical dosing | Cardiovascular-prevention dosing range: 10-80 mg PO once daily (any time of day — no peak-synthesis timing requirement). Typical starting dose 10-40 mg/day; titrate per LDL target. No specific oncology- prevention dose. Hepatic impairment: start at 10 mg. Renal impairment: start at 10 mg if CrCl <30. Hepatic monitoring (baseline LFTs); CK only if symptomatic. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-05-18 |
Notes
STUB — v0.2 chemoprevention-workstream authoring (batch 3); pending two- Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. STATIN CLASS-DETAIL entity. Primary clinical use remains cardiovascular. Pravastatin's main niche: extensive polypharmacy or muscle-symptom intolerance to other statins (lowest myopathy and DDI burden among statins; hydrophilic, no CYP3A4 substrate). Cancer-incidence signals from observational meta- analyses are modest and have NOT translated to RCT-level cancer- prevention recommendations. Limited availability in Ukraine — engine should not surface this option for UA-resident patients without confirming pharmacy availability.
Used By
No reverse references found in the YAML corpus.